Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations.
NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) — A single clinical readout drove Tenax Therapeutics (TENX) shares down approximately 84% to 85% after the Company disclosed that its the Phase 3 LEVEL trial of TNX-103 missed its primary and key secondary endpoints. If you suffered a loss on your Tenax Therapeutics investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
The reported results show a placebo-adjusted improvement in six-minute walk distance of 3.5 meters — not statistically significant — and essentially no difference from placebo on the Kansas City Cardiomyopathy Questionnaire symptom score. Topline data had been guided to August 2026, moved up from the third quarter of 2026. Exploratory measures, including a reported 49% reduction in NT-proBNP, were also disclosed alongside the topline results, but did not alter the failed pivotal endpoints.
Levosimendan-based TNX-103 was the Company’s lead clinical program, and Tenax was pre-revenue. In an April 22, 2026 press release attached to a Form 8-K, the Company described itself as expanding its “registrational program globally” and characterized levosimendan’s future as “potentially the first available therapy for PH-HFpEF patients.” The investigation concerns whether the regulatory and clinical risks associated with TNX-103 were adequately disclosed to investors.
Shareholders who lost money on TENX are encouraged to have their losses reviewed at no cost or call (212) 363-7500.
WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
Frequently Asked Questions About the TENX Investigation
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Tenax Therapeutics made materially false or misleading statements regarding the status and prospects of its Phase 3 LEVEL program for TNX-103. After the Company disclosed that the trial missed its primary and key secondary endpoints, the stock price declined approximately 84% to 85%.
Q: How much did TENX stock drop? A: Shares fell approximately 84% to 85% after the Company disclosed the failed Phase 3 LEVEL endpoints. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: Who is eligible to participate in the TENX investigation? A: Investors who purchased TENX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: What do TENX investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.
Q: What if I already sold my TENX shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TENX and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
